CoChat

Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Effective prophylactic therapies have not been established for hepatocellular carcinoma recurrence. Peretinoin represents one novel option for patients with hepatitis C virus-related hepatocellular carcinoma (HCV-HCC), and it was tested in a multicenter, randomized, double-blind, placebo-controlled study. METHODS: Patients with curative therapy were assigned to one of the following regimens: peretinoin 600, 300 mg/day, or placebo for up to 96 weeks. The primary outcome was recurrence-free survival (RFS). RESULTS: Of the 401 patients initially enrolled, 377 patients were analyzed for efficacy. The RFS rates in the 600-mg group, the 300-mg group, and the placebo group were 71.9, 63.6, and 66.0 % at 1 year, and 43.7, 24.9, and 29.3 % at 3 years, respectively. The primary comparison of peretinoin (300 and 600-mg) with placebo was not significant (P = 0.434). The dose-response relationship based on the hypothesis that "efficacy begins to increase at 600 mg/day" was significant (P = 0.023, multiplicity-adjusted P = 0.048). The hazard ratios for RFS in the 600-mg group vs. the placebo group were 0.73 [95 % confidence interval (CI) 0.51-1.03] for the entire study period and 0.27 (95 % CI 0.07-0.96) after 2 years of the randomization. Common adverse events included ascites, increased blood pressure, headache, presence of urine albumin, and increased transaminases. CONCLUSIONS: Although the superiority of peretinoin to placebo could not be validated, 600 mg/day was shown to be the optimal dose, and treatment may possibly reduce the recurrence of HCV-HCC, particularly after 2 years. The efficacy and safety of peretinoin 600 mg/day should continue to be evaluated in further studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00535-014-0956-9

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow diagram of study patients
Fig. 1 Flow diagram of study patientsCC BY-NC · PubMed Central
Fig. 2 Kaplan–Meier curves for recurrence-free survival
Fig. 2 Kaplan–Meier curves for recurrence-free survivalCC BY-NC · PubMed Central
Fig. 3 a Exploratory, post-hoc, subgroup analysis of hazard ratio for recurrence-free survival. b Exploratory, post-hoc, subgroup analysis for recurrence-free survival
Fig. 3 a Exploratory, post-hoc, subgroup analysis of hazard ratio for recurrence-free survival. b Exploratory, post-hoc, subgroup analysis for recurrence-free survivalCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 91

Metadata

Authors
Peretinoin Study Group, Okita, K., Izumi, N., Matsui, O., Tanaka, K., Kaneko, S., Moriwaki, H., Ikeda, K., Osaki, Y., Numata, K., Nakachi, K., Kokudo, N., Imanaka, K., Nishiguchi, S., Okusaka, T., Nishigaki, Y., Shiomi, S., Kudo, M., Ido, K., Karino, Y., Hayashi, N., Ohashi, Y., Makuuchi, M., & Kumada, H.
Affiliations
  • Musashino Red Cross Hospital (JP)
  • Kanazawa University Hospital (JP)
  • Yokohama City University Medical Center (JP)
  • Gifu University Hospital (JP)
  • Osaka Red Cross Hospital (JP)
  • University of Tokyo Hospital (JP)
  • Osaka International Cancer Institute (JP)
  • Hyogo Medical University Hospital (JP)
  • Gifu Municipal Hospital (JP)
  • Kindai University Hospital (JP)
  • Sapporo Kosei General Hospital (JP)
  • Kansai Rosai Hospital (JP)
  • Japanese Red Cross Medical Center (JP)
  • Japanese Red Cross Society, Japan (JP)
  • Toranomon Hospital (JP)
Corresponding author
Okita, Kiwamu
Venue
Journal of Gastroenterology
Published
2014-04-13
Volume
50
Issue
2
Pages
191-202
ISSN
  • 0944-1174 (ISSN-L)
  • 1435-5922
OpenAlex
W2022144305
Cited by
90
References
34
Citations by year
2026: 3 · 2025: 2 · 2024: 7 · 2023: 9 · 2022: 5 · 2021: 9 · 2020: 11 · 2019: 7 · 2018: 9 · 2017: 8 · 2016: 4 · 2015: 9 · 2014: 7
FWCI
5.21
Type
journal article
Language
en
Open access
Locations
  • Journal of Gastroenterology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Taiho Pharmaceutical
  • Nihon Medi-Physics
  • Kowa Company
  • Boehringer Ingelheim Japan
  • Nippon Shinyaku
  • Dainippon Sumitomo Pharma
  • Eisai
  • Kyowa Hakko Kirin
  • Astellas Pharma
  • Otsuka Pharmaceutical
  • Ajinomoto Pharmaceuticals
  • Mitsubishi Tanabe Pharma Corporation
  • Ono Pharmaceutical
  • Chugai Pharmaceutical
  • Japan Society for the Promotion of Science (221S0001)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
recurrent hepatocellular carcinoma, recurrence-free survival, adjuvant therapy, dose-response relationship, curative treatment, hepatoprotection, adverse events
MeSH terms
Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Retinoids, Anticarcinogenic Agents, Treatment Outcome, Disease-Free Survival, Hepatitis C, Chronic, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. https://app.cochat.ai/papers/10.1007/s00535-014-0956-9
The paper
Peretinoin Study Group, Okita, K., Izumi, N., Matsui, O., Tanaka, K., Kaneko, S., Moriwaki, H., Ikeda, K., Osaki, Y., Numata, K., Nakachi, K., Kokudo, N., Imanaka, K., Nishiguchi, S., Okusaka, T., Nishigaki, Y., Shiomi, S., Kudo, M., Ido, K., . . . Kumada, H. (2015). Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. Journal of Gastroenterology. https://doi.org/10.1007/s00535-014-0956-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.